ScripA look forward at the potential 2030 company rankings by prescription (Rx) and over-the-counter (OTC) sales, according to Evaluate consensus forecasts, reveals a competitive landscape being reshaped
Pink SheetAurobindo Pharmaceuticals seems confident its all-cash $250m acquisition of Pennsylvania-based Lannett Co. will pass US Federal Trade Commission scrutiny and disclosed plans to increase US producti
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Sandoz, Lupin In Lucentis Biosimil
ScripA day after posting promising results from two Phase III trials in Sjögren’s syndrome , Novartis reported ianalumab plus eltrombopag met the primary endpoint in the Phase III VAYHIT2 trial in patient